Map Pharmaceuticals Asthma Treatment Arrives at Phase II
Posted on: Friday, 4 August 2006, 12:00 CDT
Map Pharmaceuticals has initiated a phase II clinical trial evaluating Map0010, its nebulized formulation of budesonide, for the inhalation treatment of asthma in both pediatric and adult populations.
This novel approach to therapy is intended to provide the same efficacy as the currently marketed nebulizer product, but with a lower dose delivered in less time.
The phase II clinical trial will assess the efficacy of two doses of Map0010 and will be conducted at multiple clinical sites in the US as a randomized, double-blind, placebo-controlled study in approximately 225 pediatric and adolescent asthma patients.
The primary endpoint for the study will be asthma control, as assessed by changes in daily and evening asthma symptoms (coughing, wheezing, breathlessness) compared to placebo, with secondary endpoints that will evaluate changes in pulmonary function. Safety evaluations will be made throughout the duration of the clinical trial period.
"We are optimistic that the unique features of our proprietary formulation will demonstrate significant delivery advantages and rapid therapeutic benefit to patients over existing asthma treatments," said Dr Stephen Shrewsbury, vice president of clinical and regulatory affairs at Map.
Source: Datamonitor
Related Articles
- MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients With Asthma
- BioWa, Inc. Begins Phase 1 Clinical Trial in Asthma
- Tanox Initiates Phase 1 Clinical Trial Evaluating TNX-650 for Treatment of Asthma
- AIR2 Clinical Trial Begins at Baptist Hospital West; Study to Focus on Treatment That May Change the Face of Asthma Care
- Critical Therapeutics Completes Clinical Trial of Intravenous Zileuton in Patients With Asthma; Preliminary Results to Be Reported By End of Third Quarter
- deCODE Announces Positive Results From Preliminary Phase II Clinical Trial of CEP-1347 in Asthma
- CombinatoRx Reports Positive Results for CRx-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial
- Virginia Hospital Center One of 20 US Institutions Participating in Asthma Clinical Trial
- New Clinical Trial of Investigational Treatment for Asthma Begins at St. Vincent's Hospital Manhattan
- Clinical Trial Measures Ability of Focused Heat Treatment to Reduce Asthma Symptoms
 |
 |
User Comments (0)
RSS Feeds